MPH MD - Tevogen Bio CEO CoFounder
| TVGN Stock | 1.18 0.13 9.92% |
CEO
MPH MD is CEO CoFounder of Tevogen Bio Holdings
| Address | 15 Independence Boulevard, Warren, NJ, United States, 07059 |
| Phone | 877-838-6436 |
| Web | https://tevogen.com |
Tevogen Bio Management Efficiency
The company has return on total asset (ROA) of (0.8346) % which means that it has lost $0.8346 on every $100 spent on assets. This is way below average. Tevogen Bio's management efficiency ratios could be used to measure how well Tevogen Bio manages its routine affairs as well as how well it operates its assets and liabilities. As of the 3rd of December 2024, Return On Tangible Assets is likely to drop to -0.0041. In addition to that, Return On Capital Employed is likely to drop to -0.0007. As of the 3rd of December 2024, Total Assets is likely to drop to about 16.2 M. In addition to that, Non Current Assets Total is likely to drop to about 15.8 MSimilar Executives
| Found 5 records | CEO Age | ||
| James Brock | Consol Energy | 67 | |
| Patrick Goepel | Asure Software | 62 | |
| Ty Silberhorn | Apogee Enterprises | 56 | |
| Donald McNeeley | Olympic Steel | 70 | |
| Richard Marabito | Olympic Steel | 60 | |
Management Performance
| Return On Asset | -0.83 |
Tevogen Bio Holdings Leadership Team
Elected by the shareholders, the Tevogen Bio's board of directors comprises two types of representatives: Tevogen Bio inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Tevogen. The board's role is to monitor Tevogen Bio's management team and ensure that shareholders' interests are well served. Tevogen Bio's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Tevogen Bio's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Susan MBA, Independent Officer | ||
| Mittul Mehta, Chief Tevogenai | ||
| Sadiq Khan, Chief Officer | ||
| Jeffrey MPH, Member Officer | ||
| Tapan Shah, Head Development | ||
| Kirti CPA, Chief Officer | ||
| Kirti Desai, CFO Director | ||
| Sadiq MBA, Chief Officer | ||
| Neal MD, Global Officer | ||
| Stephen MBA, Chief Officer | ||
| MPH MD, CEO CoFounder | ||
| MD MPH, CEO CoFounder |
Tevogen Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Tevogen Bio a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Asset | -0.83 | ||||
| Current Valuation | 258.98 M | ||||
| Shares Outstanding | 164.61 M | ||||
| Shares Owned By Insiders | 96.61 % | ||||
| Shares Owned By Institutions | 4.58 % | ||||
| Number Of Shares Shorted | 774.71 K | ||||
| EBITDA | 188.71 K | ||||
| Net Income | (67.33 K) | ||||
| Total Debt | 1.63 M | ||||
| Cash Flow From Operations | (1.38 M) |
Pair Trading with Tevogen Bio
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Tevogen Bio position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Tevogen Bio will appreciate offsetting losses from the drop in the long position's value.Moving against Tevogen Stock
| 0.68 | A | Agilent Technologies | PairCorr |
| 0.66 | ME | 23Andme Holding | PairCorr |
| 0.47 | DOMH | Dominari Holdings | PairCorr |
| 0.43 | DRMA | Dermata Therapeutics | PairCorr |
| 0.37 | VALN | Valneva SE ADR | PairCorr |
The ability to find closely correlated positions to Tevogen Bio could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Tevogen Bio when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Tevogen Bio - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Tevogen Bio Holdings to buy it.
The correlation of Tevogen Bio is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Tevogen Bio moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Tevogen Bio Holdings moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Tevogen Bio can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Tevogen Bio Holdings. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price. You can also try the Price Exposure Probability module to analyze equity upside and downside potential for a given time horizon across multiple markets.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Tevogen Bio. If investors know Tevogen will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Tevogen Bio listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Return On Assets (0.83) |
The market value of Tevogen Bio Holdings is measured differently than its book value, which is the value of Tevogen that is recorded on the company's balance sheet. Investors also form their own opinion of Tevogen Bio's value that differs from its market value or its book value, called intrinsic value, which is Tevogen Bio's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Tevogen Bio's market value can be influenced by many factors that don't directly affect Tevogen Bio's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Tevogen Bio's value and its price as these two are different measures arrived at by different means. Investors typically determine if Tevogen Bio is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Tevogen Bio's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.